Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D [bidaily] and Q.I.D [once daily] Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study.

Next Previous
Search
Trial Profile

A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D [bidaily] and Q.I.D [once daily] Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 6370 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 02 Dec 2010 Actual initiation date changed from (Oct 2007) to (Feb 2008) as reported by ClinicalTrials.gov.
    • 28 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
    • 24 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top